Vyome Holdings shares are trading higher after the company announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds.

Vyome Reports Positive Phase 2 Results for VT-1953 in Malignant Fungating Wounds

Vyome Holdings Inc. announced positive Phase 2 results for VT-1953 topical gel in treating malignant fungating wounds. The gel met primary and secondary endpoints, and the company plans a Phase III trial aiming for FDA approval. Vyome is well-capitalized through 2026 and targets a $1 billion market. Results were presented, and the news was generated by Public Technologies using AI.

Vyome Holdings Files Prospectus Related To Resale Of 610,185 Shares Of Common Stock By Selling Stockholders

Nov 26 (Reuters) - Vyome Holdings Inc:* VYOME HOLDINGS INC - FILES PROSPECTUS RELATED TO RESALE OF 610,185 SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS Source text: Further company coverage:

Vyome Holdings Appoints Dr. Aditya Bardia as Senior Medical Advisor

Vyome Holdings Inc. has appointed Dr. Aditya Bardia as Senior Medical Advisor to guide the clinical development of VT-1953 for treating malignant fungating wounds.

Vyome Holdings Inc. Files Initial Beneficial Ownership Statement for Director Stanley D. Pomichter

Vyome Holdings Inc. has filed a Form 3 with the U.S. SEC, naming Stanley D. Pomichter III as a Director. This filing is for initial beneficial ownership and was published via EDGAR on November 19, 2025. The information is provided by Public Technologies using AI and is for informational purposes only.